# sermorelinmeds.com # Sermorelin Meds — Independent research summaries on sermorelin acetate (GHRH 1-29) > A schematic reading room for the sermorelin literature: 29-amino-acid GHRH(1-29) mechanism, the 1997 FDA approval and 2008 discontinuation, current 503A compounding status, and what the controlled trials actually show. A signal-path reading of the only GHRH-R agonist with a real FDA-approval history — pediatric efficacy, adult somatopause trials, and the 2013 Federal Register determination that keeps it in pharmacy compounding today. ## The short version: what sermorelin actually does Sermorelin is a synthetic 29-amino-acid peptide that matches the active end of the brain's own growth hormone-releasing hormone (GHRH — the signal the hypothalamus sends to tell the pituitary to make growth hormone). It does not contain growth hormone itself. Instead it prompts the pituitary gland to release the body's own GH in its natural rhythm, keeping the built-in feedback brakes intact. It was once an FDA-approved drug, sold as Geref, used to treat GH deficiency in children and to test pituitary function. The commercial product was pulled in 2008 for manufacturing reasons, not safety ones. Today it is compounded by licensed pharmacies under Category 1 of the FDA's 503A policy. For what the research actually measured — growth in GH-deficient children, body composition in older adults, cognition — see [the research page](/research). For what people in research-use communities report, and the cautions that apply, see [the effects page](/effects). ## What sermorelin is Sermorelin is a 29-amino-acid synthetic peptide. It corresponds to the N-terminal fragment of human growth hormone-releasing hormone (GHRH) — the shortest piece of the 44-residue parent hormone that retains full biological activity at the GHRH receptor [1][13]. As an acetate salt, it carries a molecular weight of 3,357.93 Da and the CAS number 86168-78-7. The amidated C-terminus is required for receptor binding; lose the amide and the molecule loses its grip on the receptor it was built to address. In pharmacologic terms, sermorelin is a **growth hormone secretagogue**. It does not contain growth hormone. It causes the pituitary to release the patient's own endogenous GH — and only as much as the pituitary's intact feedback loops permit [11][12]. ## The signal path, end to end The mechanism is a discrete, named cascade. Sermorelin binds the GHRH receptor (GHRH-R) — a class B G-protein-coupled receptor on anterior-pituitary somatotrophs — and activates Gsα-coupled adenylyl cyclase. Cyclic AMP rises. Protein kinase A phosphorylates CREB. Pit-1-mediated transcription drives growth hormone synthesis, and a discrete physiologic pulse of GH leaves the pituitary [13]. That single pulse triggers hepatic synthesis of insulin-like growth factor 1 (IGF-1), which mediates most of GH's downstream tissue effects and is the standard blood marker for monitoring the axis. The circuit is closed-loop. Somatostatin opposes GHRH at the somatotroph; rising IGF-1 feeds back to suppress further GH release. Because sermorelin works upstream of those brakes — rather than bypassing them, the way exogenous recombinant GH does — output is self-limiting. The 2025 Frontiers in Aging clinical review names this property explicitly: pulsatile, feedback-regulated GH release is a mechanistically distinct safety paradigm versus continuous rhGH replacement [15]. ## Why a site about a compound you can no longer buy as a finished drug Sermorelin occupies an unusual position in the U.S. drug catalog. It was approved by the FDA in 1997 under NDA 020443 for pediatric idiopathic growth hormone deficiency and for diagnostic GH stimulation testing. The original manufacturer voluntarily discontinued commercial production in 2008. Marketing approval was withdrawn in 2009. Then, on March 4, 2013, the FDA published a Federal Register determination (78 FR 14114) finding that the product was **not** withdrawn from sale for reasons of safety or effectiveness. The discontinuation was attributed to manufacturing-process difficulties with the active pharmaceutical ingredient — a commercial decision, not a regulatory one [18]. That determination is the regulatory predicate that anchors current pharmacy practice. Sermorelin appears on Category 1 of the FDA's interim 503A Bulks List, meaning the agency has indicated it does not currently intend to take enforcement action against compounders preparing sermorelin from a bulk substance, pending final Pharmacy Compounding Advisory Committee review. In 2026, all U.S. sermorelin reaches patients through 503A or 503B compounding pharmacies — never as an FDA-approved finished product. ## What the controlled trials actually show The clinical record is unusually substantial for a peptide that currently has no approved finished formulation: - **Pediatric efficacy.** The international multicenter pivotal trial reported mean height velocity rising from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months and 7.2 ± 1.3 cm/yr at twelve months in prepubertal children with idiopathic GHD on 30 µg/kg subcutaneous nightly dosing. Seventy-four percent were classified as good responders at six months [1][2]. - **Idiopathic short stature.** A separate trial in children without classical GHD also reported a sustained increase in growth velocity, suggesting GHRH(1-29) augments the GH axis even when baseline stimulation tests do not meet GHD diagnostic thresholds [5]. - **Adult somatopause.** Twice-daily subcutaneous GHRH(1-29) at 1 mg restored mean 24-hour GH and IGF-1 in healthy older men to values not significantly different from healthy young controls; elevated IGF-1 persisted approximately two weeks after dosing stopped [3]. Sixteen weeks of nightly subcutaneous [Nle27]GHRH(1-29)-NH2 at 10 µg/kg in adults 55-71 increased lean body mass by about 1.26 kg in men, improved insulin sensitivity in men, and increased skin thickness in both sexes [4]. - **Cognition.** Twenty weeks of nightly GHRH-analog dosing in adults 55-87 significantly improved executive function (p = .005), raised IGF-1 by 117%, and decreased body fat by 7.4% [7]. Magnetic-resonance spectroscopy in the same population documented increased GABA, increased N-acetylaspartylglutamate, and decreased myo-inositol — a candidate neurochemical mechanism for the cognitive findings [8]. The FDA-era safety record is mild and stereotyped. The most common treatment-related event was transient injection-site reaction in about one in six pediatric patients; other events ran below 1%. No clinically significant changes in serum chemistries, thyroid function, or glucose tolerance were observed in the registration trials [10]. ## How to use this site Every page is a board. Every section carries a designator (U·01, R·02, C·03, D·04, J·05) — short marks borrowed from electronic-component vocabulary that anchor each topic to a position in the literature catalog. The **/research** page walks the mechanism, the pediatric and adult trial record, and the more recent cognitive and exosome-biomarker work [7][8][17]. The **/dosage** page documents the historic FDA-labeled regimens and the research-context doses used in adult trials — strictly as descriptive history, never as a recommendation. The **/faq** page answers the questions a careful reader of the literature actually asks: is sermorelin still made, why was it discontinued, what does the half-life imply, how does it compare to recombinant GH. The **/references** page lists every citation with DOI and PubMed identifiers. The **/about** page describes what this publisher is and is not. This site does not sell sermorelin. It does not prescribe sermorelin. It does not employ clinicians. It is an editorial reading room for the published research, organized so a reader — human or machine — can trace any claim on the page back to the primary source it came from. --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription. --- # Sermorelin reported effects and safety — BOARD E·04 > What the controlled trials measured, what research-use communities report, and the safety cautions that apply to sermorelin (GHRH 1-29). Evidence kept plainly distinct from anecdote. Measured trial outcomes, research-community signals, and the cautions that apply to GHRH(1-29) — each layer kept clearly separate. ## BOARD E·04 · before the details Here is the honest state of sermorelin effects in plain words. Sermorelin tells the pituitary gland to release the body's own growth hormone (GH), so the effects it produces are downstream growth-hormone effects — not the same as injecting growth hormone directly. The pituitary's built-in feedback brakes stay in place, which limits how far GH can climb. The controlled human evidence is concentrated in two populations: children with growth-hormone deficiency, and healthy older adults. Outside those groups, the trial record is thin. The wellness and anti-aging uses that circulate in research communities are not backed by large long-term trials [19]. This page separates what the published studies actually measured, what community members report anecdotally, and what the evidence-based cautions are. ## What the studies measured The controlled trial record is focused and traceable. **Growth in children with GH deficiency.** In a multicenter international trial, once-daily subcutaneous sermorelin at 30 µg/kg at bedtime raised mean height velocity from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months; 74% of prepubertal children were classified as good responders. No excess IGF-1 generation was observed [1]. A concurrent review confirmed catch-up growth through twelve months with a mild, stereotyped side-effect profile [2]. **GH and IGF-1 restoration in older men.** Twice-daily subcutaneous GHRH(1-29) at 1 mg for 14 days restored 24-hour GH and IGF-1 in healthy men aged 60-78 to values not significantly different from healthy young men, with no change in fasting glucose [3]. **Body composition and cognitive function in older adults.** Sixteen weeks of nightly subcutaneous [Nle27]GHRH(1-29)-NH2 at 10 µg/kg in adults aged 55-71 increased lean body mass by ~1.26 kg in men, improved insulin sensitivity, and increased skin thickness in both sexes [4]. A randomized trial of a related GHRH analog taken nightly for 20 weeks in 152 adults aged 55-87 significantly improved executive function (p = .005), raised IGF-1 by 117%, and reduced body fat by 7.4% [7]. **Sleep and neurochemistry.** In a companion MRS study, 20 weeks of GHRH analog dosing increased brain GABA in three regions, increased N-acetylaspartylglutamate in the frontal cortex, and decreased myo-inositol in the posterior cingulate — a coherent neurochemical pattern consistent with the cognitive findings [8]. All of these are research-context findings from specific trial populations. They describe what was measured in those studies, not outcomes available to anyone choosing to use sermorelin today. ## What people report **These are community-sourced signals — anecdotal, not clinical evidence — drawn from research-use forums, telehealth patient write-ups, and consumer review sites. They are included for honest context, not as outcomes you should expect or that the trial record supports.** **Benefits reported:** - **Deeper, more restful sleep and vivid dreams** (very commonly reported). The single most-mentioned reason people try sermorelin. Community members describe falling asleep faster, sleeping more deeply, and noticing vivid dreams within the first couple of weeks — consistent with GH release being tied to slow-wave sleep. - **More daytime energy and faster exercise recovery** (frequently reported). People describe a gradual lift, not a stimulant effect, often crediting better sleep rather than a direct stimulant action. - **Gradual body-fat reduction** (frequently reported). Modest reductions over several months, mostly around the midsection, are commonly described in clinic write-ups. Results vary and depend on diet, exercise, and daily consistency. - **Improved muscle tone, skin, and sense of well-being** (occasionally reported). Subjective and easy to confuse with the effects of better sleep; these are anecdotes, not measured outcomes. **Adverse effects reported:** - **Injection-site redness, itching, or swelling** (very commonly reported). The most common complaint, matching what the controlled pediatric trials recorded. Usually mild and short-lived; rotating sites is the standard community approach. - **Headache, facial flushing, or brief dizziness** (frequently reported). Usually in the first week or two, fading as the body adjusts. - **Water retention or puffiness** (occasionally reported). Attributed to rising IGF-1; eases when exposure is reduced. - **Drowsiness after the evening dose** (occasionally reported). Expected from nighttime dosing; a few report next-morning grogginess. - **Tingling or numbness in the hands** (rarely reported). Associated by the community with fluid retention at higher sustained exposure; described as reversible when recognized early. - **Slow and gradual overall** (frequently noted). Community advice consistently emphasizes that the first month may feel like nothing is happening; benefits accumulate over the second and third month with daily consistency. ## Safety and cautions The cautions below are grounded in published evidence and mechanistic reasoning. They are not a complete safety assessment; people considering sermorelin should consult a qualified clinician working from current clinical literature. **Long-term wellness benefit is not proven.** Sermorelin is widely positioned for anti-aging and vitality, but large, long-term trials do not exist for those uses. A 2008 Annals of Internal Medicine editorial concluded that using growth-hormone secretagogues to prevent or treat aging is 'not yet ready for prime time' [19]. People should treat strong wellness claims with skepticism. **Theoretical cancer risk from chronically elevated GH/IGF-1.** Growth hormone and IGF-1 can promote cell growth. Chronically raising them carries a theoretical malignancy-related risk. Sermorelin's pulsatile, feedback-controlled mechanism may limit peak IGF-1 compared with direct GH replacement, but this theoretical concern has not been resolved by long-term human data [20]. The historic label listed active malignancy and unevaluated pituitary mass as principal contraindications [10][11]. **Blood-sugar effects, especially in older or pre-diabetic individuals.** Growth hormone antagonizes insulin. In a study of a PEG-conjugated GHRH peptide in elderly subjects, repeated dosing was associated with impaired glucose tolerance [21]. People who are older, pre-diabetic, or have metabolic syndrome should be especially alert and have glucose monitored. **Mild injection-site and transient metabolic shifts.** Human studies of GHRH(1-29) and related peptides consistently identify injection-site irritation as the most common side effect. Transient minor changes such as small rises in blood lipids were also recorded in some trials; these resolved and were generally mild [10]. **Pulsatile dosing is required; continuous infusion blunts response.** The GH axis is built to fire in pulses. When GHRH(1-29) was given as a continuous subcutaneous infusion in children, the GH response faded after a few months and was fully suppressed in one participant. Intermittent, once-daily use avoids this desensitization — the design intent behind bedtime nightly dosing [10]. **Prohibited in sport.** Sermorelin is a WADA-prohibited substance (Section S2). Athletes subject to anti-doping rules should treat the WADA classification as definitive [22]. **Gray-market product quality.** Sermorelin sold outside a licensed compounding-pharmacy supply chain may be mislabeled or contaminated. Rigorous human safety data for unregulated use are scarce. ## Then and now: Geref to 503A compounding Sermorelin has a genuine FDA-approval history that is often misstated. It was approved as the prescription drug Geref (sermorelin acetate, NDA 020443) for two indications: to treat growth-hormone deficiency in children with short stature, and to test how well the pituitary could release growth hormone. A multicenter trial in GH-deficient children demonstrated that once-daily injections sped up height growth in the first year [1], and a clinical review documented its diagnostic and pediatric treatment roles [2]. In 2008 the branded product was voluntarily withdrawn from the U.S. market for commercial manufacturing reasons, not because of any safety or effectiveness problem. The FDA confirmed this formally in a Federal Register determination published March 4, 2013 (78 FR 14114) [18]. That non-safety, non-efficacy finding is the regulatory anchor that permits licensed 503A compounding pharmacies to prepare sermorelin today. The current anti-aging and wellness use of compounded sermorelin is off-label and is not the same as its former FDA-approved indication. --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription. --- # Sermorelin research literature — mechanism, pediatric efficacy, adult somatopause trials > A traced summary of the sermorelin research record: GHRH-R signaling cascade, 1996 pivotal pediatric trial, adult aging-axis controlled studies, GHRH-analog cognitive trials, and the GHRH-R receptor distribution that is widening the analog class beyond pituitary GH release. Mechanism, pediatric efficacy, adult somatopause, cognitive effects, and the post-FDA-approval regulatory landscape — each finding traced to its primary source. ## The short version: what the studies found The sermorelin research record is unusually rich for a peptide that currently has no approved finished formulation. The core human evidence covers three areas. In children with growth hormone deficiency, once-daily subcutaneous injections roughly doubled the rate of height growth in the first year of a multicenter trial. In healthy older men, twice-daily doses restored GH and IGF-1 — a hormone the liver makes in response to GH — to levels seen in younger adults. In adults aged 55 to 87, a related GHRH analog taken nightly for 20 weeks improved executive function and reduced body fat in a randomized, placebo-controlled trial. Beyond the pituitary, GHRH receptors appear in heart tissue, immune cells, and several other organs, which has opened a frontier of preclinical research on wound healing and other applications. All of that remains early-stage. The pages below trace each finding to its primary source. ## Mechanism: the cAMP-PKA-CREB cascade Sermorelin is the prototype of the GHRH-R agonist class. It binds the growth hormone-releasing hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed on anterior-pituitary somatotroph cells. Receptor occupancy activates the heterotrimeric Gs protein; the α-subunit stimulates adenylyl cyclase; intracellular cAMP rises sharply; protein kinase A is activated; CREB is phosphorylated; and the somatotroph-specific transcription factor Pit-1 drives growth hormone gene transcription and secretion [13]. A 2025 review in Reviews in Endocrine and Metabolic Disorders maps the receptor's distribution carefully. GHRH-R is expressed not only on pituitary somatotrophs but also in myocardium, lymphocytes, testes, ovaries, skin, placenta, kidney, pancreas, and many human tumor tissues [13]. That distribution is what underlies the expanding research interest in GHRH-analog effects beyond pituitary GH release — cardiovascular, regenerative, immune, oncologic — even though sermorelin's own clinical record sits almost entirely in the pituitary-GH lane. A 2024 Nature Reviews Endocrinology consolidation reinforces the same picture: sermorelin is the prototype of a drug class whose clinical scope is widening from somatotroph GH release into cancer, regenerative medicine, cardiovascular protection, and metabolic disease [16]. ## The pediatric efficacy record The historic FDA approval rested principally on a multicenter international trial in prepubertal children with idiopathic growth hormone deficiency. Once-daily subcutaneous sermorelin at 30 µg/kg at bedtime increased mean height velocity from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months and 7.2 ± 1.3 cm/yr at twelve months. Seventy-four percent of children were classified as good responders at six months. No adverse changes in glucose homeostasis or in IGF-1 outside the expected range were observed [1]. A contemporary BioDrugs review of pediatric sermorelin practice concluded that the 30 µg/kg nightly regimen sustained height-velocity increases over twelve months and induced catch-up growth in the majority of prepubertal GHD children, with transient facial flushing and injection-site pain as the most common adverse events. Intravenous sermorelin at 1 µg/kg also functioned as a relatively specific provocative GH stimulation test, with fewer false positives than other stimulation modalities in the same review [2]. A separate trial extended the question to children with idiopathic short stature who did not meet classical GHD diagnostic criteria. GHRH(1-29)-NH2 treatment in this population produced a sustained increase in growth velocity — evidence that GHRH-R agonism augments the somatotropic axis even when baseline stimulation tests fall above the GHD threshold [5]. ## The adult aging-axis record Two controlled studies anchor the adult somatopause literature: Corpas and colleagues (1992) treated healthy older men (60-78 years) with 0.5 mg or 1.0 mg subcutaneous GHRH(1-29) twice daily for 14 days. The 1 mg dose restored mean 24-hour GH levels, peak GH amplitude, and IGF-1 concentrations to values not significantly different from healthy young men (22-33 years). Elevated IGF-1 persisted approximately two weeks after dosing stopped. No clinically significant changes in glucose, blood pressure, or routine laboratory values were recorded [3]. Khorram and colleagues (1997) dosed adults aged 55-71 (n=19) with nightly subcutaneous [Nle27]GHRH(1-29)-NH2 at 10 µg/kg for 16 weeks after a 4-week placebo lead-in. Nocturnal GH and IGF-1 rose. Lean body mass increased by approximately 1.26 kg in men. Insulin sensitivity improved in men. Skin thickness — a dermal collagen marker — increased in both sexes. Subjective measures of well-being also improved [4]. These two trials are the canonical adult-somatopause GHRH(1-29) controlled studies. A 2025 clinical review of growth hormone and aging frames pulsatile, feedback-regulated GHRH stimulation as mechanistically distinct from continuous rhGH replacement and identifies pulsatility preservation as a key safety advantage in age-related research [15]. ## Cognitive trials in older adults The most striking modern data come from a randomized placebo-controlled trial at the University of Washington. Baker and colleagues (2012) dosed 137 adults aged 55-87 — 76 healthy controls and 61 with mild cognitive impairment — with 1 mg of subcutaneous tesamorelin (a stabilized GHRH analog mechanistically analogous to sermorelin) nightly for 20 weeks. Executive function improved significantly (p = .005), with a trend toward improved verbal memory (p = .08). IGF-1 rose 117%. Body fat fell 7.4% [7]. A companion magnetic-resonance spectroscopy study by Friedman and colleagues (2013) probed the neurochemistry behind the cognitive findings. After 20 weeks of GHRH-analog dosing, GABA increased in all three brain regions assayed, N-acetylaspartylglutamate increased in the frontal cortex, and myo-inositol decreased in the posterior cingulate — a coherent pattern of neurochemical change consistent with the observed cognitive benefit [8]. A 2018 follow-on by Winston and colleagues looked at neuronal-derived exosomal biomarkers in the same trial population. Twenty weeks of GHRH-analog administration favorably modulated exosomal markers of synaptic and inflammatory pathways in adults with mild cognitive impairment, supporting a biological mechanism for the cognitive findings reported in the parent Baker trial [17]. The Baker and Friedman trials use tesamorelin rather than sermorelin proper. Tesamorelin is a stabilized GHRH analog that shares sermorelin's mechanism — same receptor, same downstream cascade — with a longer functional half-life. An earlier study by Vitiello and colleagues (2006) used GHRH(1-29) itself daily for 6 months in 89 healthy older adults and likewise reported improved executive function and global cognition, with the largest gains in subjects with lower baseline Mini-Mental State Examination scores [9]. Together the three studies establish — for a small but consistent body of evidence — that restoring the GH/IGF-1 axis in older adults via GHRH-R agonism can improve cognition in randomized, placebo-controlled designs. ## Extrapituitary signaling and the wider analog class GHRH-R is not only a pituitary receptor. Structurally related GHRH agonist analogs — MR-409, MR-356, JI-38 — have demonstrated cardioprotective effects after experimental myocardial infarction and accelerated dermal wound healing in animal models, driven by fibroblast proliferation and survival through ERK and AKT pathway activation [12]. A 2020 review of growth hormone secretagogues consolidates the mechanistic distinction between the GHRH-R agonist class (sermorelin, tesamorelin, CJC-1295) and the GHS-R/ghrelin-receptor agonist class (ipamorelin, GHRP-6, MK-0677). The two classes converge on the same somatotroph cell via independent intracellular pathways, which is why combined GHRH + GHS administration produces synergistic GH release greater than the additive sum of either alone — the pharmacologic basis underlying the common sermorelin + ipamorelin compounded co-administration pattern [16][14]. ## Regulatory state of play A 2024 update on adult growth hormone deficiency syndrome documents how materially the post-2008 worldwide commercial unavailability of pharmaceutical GHRH has changed adult GHD diagnostic practice. The GHRH + arginine and GHRH + GHRP-6 stimulation tests, once standard, are no longer feasible through standard pharmaceutical channels in many jurisdictions — establishing the practical landscape in which compounded sermorelin is, for many U.S. clinicians, the only practical GHRH-class option that remains available [14]. The regulatory anchor for that practice is the FDA's March 2013 Federal Register determination (78 FR 14114), which formally established that the prior FDA-approved sermorelin acetate injection at 0.5 mg/vial, 1.0 mg/vial, and 0.05 mg/amp was not withdrawn from sale for reasons of safety or effectiveness [18]. That non-safety, non-efficacy finding is what permits 503A and 503B compounding pharmacies to prepare sermorelin from bulk substance under the FDA's interim 503A Bulks List Category 1 enforcement-discretion posture, pending final Pharmacy Compounding Advisory Committee review. --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription. --- # Sermorelin dosing in the research and historic FDA-label record > A documentation-only summary of sermorelin dosing as it appears in the historic FDA-approved pediatric label and in published adult research trials. Includes the 30 µg/kg pediatric regimen, the 1 µg/kg diagnostic stimulation test, and the adult somatopause research doses. Research context only — not a recommendation. A documentation-only listing of the historic FDA-labeled pediatric regimen, the FDA-labeled diagnostic stimulation test, and the doses used in published adult research trials. Descriptive history, not prescriptive guidance. ## The short version: doses in the record This page documents doses as they appear in the historic FDA-approved label and in published research trials. It is not a recommendation, and there is no current FDA-approved adult sermorelin product. The pediatric label set a once-daily subcutaneous dose of 30 micrograms per kilogram of body weight at bedtime — timed to reinforce the body's natural overnight GH pulse. Adult research used a range of regimens, from twice-daily injections in a two-week study of older men to nightly injections in a 16-week body-composition trial. A related GHRH analog was used nightly for 20 weeks in cognitive trials. Sermorelin is cleared from the blood in roughly 11 to 12 minutes, which is by design: the molecule is built to produce a short, discrete GH pulse rather than continuous receptor stimulation. That short half-life is also why longer-acting analogs were developed. ## Reading note This page documents the doses that appear in the historic FDA-approved labeling and in the published research literature. It is not a recommendation. There is currently no FDA-approved finished sermorelin product on the U.S. market; all access in 2026 is through 503A or 503B compounding pharmacies on the basis of an individual patient prescription, and any dosing decision is the responsibility of the prescribing clinician working from current professional sources. The values below are reproduced because they are part of the public record of what has been studied — not because the site is suggesting any particular regimen. ## Historic FDA-labeled pediatric regimen The 1997 FDA-approved sermorelin acetate injection carried an indication for the treatment of idiopathic growth hormone deficiency in children with growth failure. The labeled regimen was **30 µg/kg subcutaneous once daily at bedtime** [1][2][6]. The bedtime timing was deliberate. Endogenous GH secretion is pulsatile, with the largest physiologic pulses during slow-wave sleep; the nightly subcutaneous dose was designed to reinforce the natural nocturnal pulse pattern rather than to drive continuous receptor stimulation. The pivotal trial of this regimen — Thorner and colleagues (1996), an international multicenter study published in JCEM — reported mean height velocity rising from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months in 74% of treated children [1]. The contemporary BioDrugs review (Prakash and Goa, 1999) reported the same regimen sustaining catch-up growth through twelve months in the majority of prepubertal GHD children [2]. ## Historic FDA-labeled diagnostic regimen Sermorelin's second FDA-approved indication was diagnostic. A **1 µg/kg intravenous bolus** was administered for provocative evaluation of pituitary GH secretory capacity, with serum GH measured at intervals afterward. In the historic literature this functioned as a relatively specific GH provocative test with fewer false positives than other stimulation modalities [2][6]. A 2024 review of adult GHD diagnostic practice notes that the worldwide commercial unavailability of pharmaceutical GHRH over the prior decade has materially changed the diagnostic landscape — the GHRH + arginine and GHRH + GHRP-6 stimulation tests, once standard, are no longer feasible through standard pharmaceutical channels in many jurisdictions [14]. ## Adult aging-axis research doses Two adult controlled trials anchor the somatopause dosing record: - **Corpas et al. 1992** — healthy men aged 60-78, **0.5 mg or 1.0 mg subcutaneous twice daily for 14 days**. The 1 mg dose restored mean 24-hour GH, peak GH amplitude, and IGF-1 to values not significantly different from healthy young men. Elevated IGF-1 persisted approximately two weeks after dosing stopped [3]. - **Khorram et al. 1997** — adults aged 55-71 (n=19), nightly subcutaneous **[Nle27]GHRH(1-29)-NH2 at 10 µg/kg for 16 weeks** after a 4-week placebo lead-in. Increased lean mass and skin thickness, improved insulin sensitivity in men [4]. A related cognitive trial used **tesamorelin 1 mg subcutaneous nightly for 20 weeks** in adults aged 55-87 — a stabilized GHRH analog rather than sermorelin proper, but mechanistically equivalent [7]. These doses are research-context values from published controlled trials. They are not labeled doses (there is no current adult sermorelin labeling) and they are not transferable to clinical practice without independent professional evaluation. ## Pharmacokinetics: short half-life by design Sermorelin is rapidly absorbed and rapidly cleared. Plasma clearance in adults is approximately **2.4-2.8 L/min**. Terminal half-life is approximately **11-12 minutes** after either intravenous or subcutaneous administration [6]. The short half-life is the design intent, not a limitation. The molecule is meant to produce a discrete physiologic GH pulse rather than sustained receptor stimulation, mimicking endogenous pulsatile GHRH signaling. Sustained GHRH-R occupancy would defeat the somatostatin and IGF-1 feedback structure that gives the molecule its self-limiting safety character [15]. It is also the principal reason that structurally stabilized analogs exist. CJC-1295 (no DAC, also called Modified GRF 1-29) substitutes amino acids in the GHRH(1-29) sequence to resist DPP-IV degradation and extend functional half-life. Tesamorelin is a separately stabilized analog that has been FDA-approved for HIV-associated lipodystrophy and used as the proxy molecule in several cognitive trials. Sermorelin itself remains the canonical pulsatile-stimulation choice where strict mimicry of endogenous GHRH pharmacokinetics is the design intent. ## Routes studied Three administration routes appear in the literature: - **Subcutaneous injection** — by far the most common, used in both the pediatric efficacy trials and the adult somatopause and cognitive trials. - **Intravenous bolus** — historically used for the diagnostic GH stimulation test only. - **Sublingual or oral troche** — appears in some compounded research formulations; bioavailability is less well characterized in peer-reviewed sources. The peptide is supplied as a lyophilized powder requiring reconstitution. Reconstituted solutions are typically refrigerated at 2-8 °C and used within a defined window per compounding pharmacy assignment. The peptide is sensitive to heat and to repeated freeze-thaw cycles. ## Safety profile in the FDA-era trial record The FDA-era safety record is mild and stereotyped. The most common treatment-related adverse event in pediatric clinical-trial datasets was a **transient injection-site reaction** (pain, swelling, or redness) occurring in approximately 1 of 6 patients. Other events reported at individual rates below 1% included headache, facial flushing, dysphagia, dizziness, hyperactivity, somnolence, and urticaria. No clinically significant changes in serum chemistries, thyroid function, or glucose tolerance were observed over the trial period [10]. The historic label listed two principal contraindications: **active malignancy** and **unevaluated pituitary mass**. Long-term elevation of IGF-1 has been associated in epidemiologic studies with theoretical increases in malignancy risk; causality remains debated, and most research protocols monitor IGF-1 and target the upper-normal age range rather than supraphysiologic values [11]. A hypothalamic GHD diagnosis cannot be ruled out by a normal sermorelin stimulation test result, because sermorelin acts at the pituitary downstream of the hypothalamus; diagnostic interpretation requires clinical context. --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription. --- # Sermorelin FAQ — research summaries on GHRH(1-29) acetate > Common reader questions about sermorelin: is it still made, why was the FDA-approved product discontinued, what is the half-life, how does it differ from rhGH, is it WADA-banned, and what does the research actually show. Plain-language answers to the questions a careful reader of the GHRH(1-29) literature actually asks. ## What is sermorelin and how is it used? Sermorelin is a 29-amino-acid synthetic peptide that corresponds to the N-terminal active fragment of human growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells and triggers a discrete, pulsatile release of the body's own growth hormone — it does not contain growth hormone itself [13]. The historic FDA-approved indications were two: treatment of idiopathic growth hormone deficiency in children with growth failure, and provocative diagnostic testing of pituitary GH secretory capacity in adults and children [1][2]. In current U.S. practice, sermorelin reaches patients exclusively through 503A or 503B compounding pharmacies on the basis of an individual prescription; it is not commercially available as an FDA-approved finished product [18]. ## Is sermorelin still made or available? Not as an FDA-approved finished drug — the previously approved manufactured product was voluntarily discontinued by its original sponsor in 2008, and FDA marketing approval was withdrawn in 2009 [18]. It remains available in the United States through 503A and 503B compounding pharmacies. Sermorelin sits on Category 1 of the FDA's interim 503A Bulks List, meaning the agency has stated it does not currently intend to take enforcement action against pharmacies preparing sermorelin from a bulk substance, pending final Pharmacy Compounding Advisory Committee review [18]. A 2024 review of adult GHD diagnostic practice notes that this is why compounded sermorelin is, for many U.S. clinicians, the only practical GHRH-class option that has remained accessible over the past decade [14]. ## Why was the FDA-approved sermorelin product discontinued in 2008? The 2008 discontinuation was a commercial decision attributed to difficulties in the manufacturing process of the active pharmaceutical ingredient — not a regulatory action and not a response to safety or efficacy findings. The FDA made this explicit in a Federal Register determination published March 4, 2013 (78 FR 14114). The agency formally found that the product at the three previously approved strengths was **not withdrawn from sale for reasons of safety or effectiveness** [18]. That non-safety, non-efficacy finding is the regulatory anchor that 503A and 503B compounding pharmacies cite when preparing sermorelin under the 'previously FDA-approved' pathway. ## What forms of sermorelin are available today? Subcutaneous injection is by far the most common research and compounded form, supplied as a lyophilized powder requiring reconstitution with bacteriostatic water for injection in research formulations or sterile water in the historic FDA-approved label. Reconstituted solutions are typically refrigerated at 2-8 °C and used within a defined window assigned by the compounding pharmacy. The peptide is sensitive to heat and to repeated freeze-thaw [6]. Sublingual and oral troche formulations also appear in some compounded research preparations; bioavailability through these routes is less well characterized in the peer-reviewed literature than the subcutaneous route. Intravenous administration appears in the literature only in the historic diagnostic context (a 1 µg/kg IV bolus for provocative GH stimulation testing) [2]. ## How does sermorelin differ from recombinant growth hormone? Recombinant human GH (rhGH) is exogenous growth hormone — the hormone itself, delivered into circulation, bypassing the pituitary entirely. Sermorelin is a GHRH analog — a signal upstream of the pituitary, asking the pituitary to release its own GH [11]. The practical implication is that sermorelin-driven GH release remains subject to intact somatostatin and IGF-1 negative feedback. Rising IGF-1 still suppresses further GH release; somatostatin tone still opposes GHRH at the somatotroph. Output is self-limiting. Exogenous rhGH has no such feedback because it bypasses the receptor that the feedback acts on. The 2025 Frontiers in Aging clinical review names this preserved pulsatility as a mechanistically distinct safety paradigm for GHRH-analog research versus continuous rhGH replacement [15][11]. ## What is the half-life of sermorelin? Approximately **11-12 minutes**, after either intravenous or subcutaneous administration. Plasma clearance in adults is approximately 2.4-2.8 L/min [6]. The short half-life is the design intent. The molecule is meant to produce a discrete physiologic GH pulse, not sustained receptor stimulation. Endogenous GHRH signals the pituitary in bursts, not a steady drip, and sermorelin's pharmacokinetics mimic that pattern. It is also the reason that structurally stabilized analogs exist. CJC-1295 (no DAC) substitutes amino acids in the GHRH(1-29) sequence to resist DPP-IV degradation; tesamorelin is a separately stabilized analog. Both extend functional half-life beyond sermorelin's. Sermorelin remains the canonical molecule where strict mimicry of endogenous GHRH pharmacokinetics is the design intent. ## What does the research say about sermorelin in children and in older adults? **In children with idiopathic growth hormone deficiency**, the pivotal international multicenter trial reported mean height velocity rising from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months on the labeled 30 µg/kg subcutaneous nightly regimen; 74% were classified as good responders at six months [1]. A contemporary review confirmed sustained catch-up growth through twelve months in the majority of treated children [2]. A separate trial in children with idiopathic short stature without classical GHD also reported a sustained increase in growth velocity [5]. **In older adults**, twice-daily 1 mg subcutaneous GHRH(1-29) restored 24-hour GH and IGF-1 in healthy men aged 60-78 to values not significantly different from young controls [3]. Sixteen weeks of nightly subcutaneous [Nle27]GHRH(1-29)-NH2 at 10 µg/kg in adults 55-71 increased lean body mass by about 1.26 kg in men, improved insulin sensitivity in men, and increased skin thickness in both sexes [4]. Twenty weeks of nightly GHRH-analog dosing in adults 55-87 significantly improved executive function (p = .005) and decreased body fat 7.4% in the Baker 2012 trial [7], with companion neurochemical and exosome-biomarker findings consistent with the cognitive improvement [8][17]. ## Why is sermorelin often paired with ipamorelin in research? The two compounds act on different receptors that converge on the same somatotroph cell. Sermorelin is a GHRH receptor agonist; ipamorelin is a ghrelin/GHS-R1a receptor agonist. The two receptor systems use independent intracellular pathways, and combined GHRH + GHS administration produces synergistic GH release that exceeds the additive sum of either compound alone [16]. A 2020 review of growth hormone secretagogues consolidates the mechanistic distinction between the two classes and reviews the synergy evidence. Sermorelin and ipamorelin together cover both arms of the somatotroph's regulatory input — which is the pharmacologic basis for the common compounded co-administration pattern in research literature [16]. ## Is sermorelin safe? What does the historical safety record show? The FDA-era pediatric trial record characterizes sermorelin's safety profile as mild and stereotyped. The most common treatment-related adverse event was a transient injection-site reaction — pain, swelling, or redness — in approximately 1 of 6 pediatric patients. Other events reported at individual rates below 1% included headache, facial flushing, dysphagia, dizziness, hyperactivity, somnolence, and urticaria. No clinically significant changes in serum chemistries, thyroid function, or glucose tolerance were observed over the trial period [10]. The historic label listed two principal contraindications: active malignancy and unevaluated pituitary mass. Long-term elevation of IGF-1 has been associated in epidemiologic studies with theoretical increases in malignancy risk; causality remains debated, and most research protocols monitor IGF-1 and target the upper-normal age range [11]. ## Is sermorelin banned by WADA? Yes. GHRH and GHRH-mimetic peptides — including sermorelin — are classified as Prohibited Substances under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the World Anti-Doping Agency (WADA) Prohibited List, prohibited both in-competition and out-of-competition. Athletes subject to anti-doping rules should treat the WADA classification as definitive. Even a therapeutic-use exemption pathway for an FDA-approved indication would be governed by the relevant federation's anti-doping authority, not by the compounding pharmacy or the prescribing clinician. ## How is sermorelin regulated by the FDA in 2026? Sermorelin's regulatory state in 2026 is layered: 1. **No FDA-approved finished product on the market.** The 1997 FDA-approved sermorelin acetate injection (NDA 020443) was voluntarily discontinued by its manufacturer in 2008, and FDA marketing approval was withdrawn in 2009 [18]. 2. **Federal Register determination of non-safety, non-efficacy basis for withdrawal.** The March 4, 2013 determination (78 FR 14114) formally established that the prior approved product at 0.5 mg/vial, 1.0 mg/vial, and 0.05 mg/amp was not withdrawn from sale for reasons of safety or effectiveness [18]. 3. **503A Bulks List Category 1.** Sermorelin appears on Category 1 of the FDA's interim 503A Bulks List, indicating that the agency does not currently intend to take enforcement action against compounders preparing sermorelin from a bulk substance, pending final Pharmacy Compounding Advisory Committee review. All U.S. patient access in 2026 is via 503A or 503B compounding pharmacies on the basis of an individual patient prescription. None of this is medical, regulatory, or legal advice; clinicians and pharmacists rely on current professional and regulatory sources, not on this site. ## How does sermorelin compare to CJC-1295? Same mechanism, different pharmacokinetics. CJC-1295 (no DAC) — sometimes called Modified GRF 1-29 — is structurally a stabilized variant of the sermorelin GHRH(1-29) sequence with amino-acid substitutions that resist degradation by the enzyme DPP-IV. The receptor activity is the same GHRH-R agonist mechanism; the practical difference is a longer functional half-life [16]. Which molecule is preferable in a given research protocol depends on whether the design calls for strict pulsatile mimicry of endogenous GHRH signaling (sermorelin) or for extended GHRH-R stimulation (CJC-1295). Both remain investigational research peptides; neither is currently an FDA-approved finished product. ## Does this site sell sermorelin? No. This is an editorial reading room for the published research literature on sermorelin and the GHRH-R agonist class. The site does not sell, distribute, manufacture, or dispense any product. It is not affiliated with any compounding pharmacy, manufacturer, or vendor. It does not employ clinicians and it does not provide medical advice. --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription. --- # Sermorelin references — full citation list with DOI and PubMed identifiers > Complete reference list for the sermorelin research summaries on this site: 18 primary and review sources spanning the 1992 Corpas trial through 2025 reviews of GHRH-R signaling and the somatopause clinical context. Every citation referenced from the mechanism, research, dosage, and FAQ pages — with DOI, PMID, and direct links to PubMed, PMC, and the source repositories. ## Reading note Citations are numbered 1 through 18 and used consistently across every page on this site. Where a single source supports a claim on multiple pages — for example, the historic FDA prescribing information [6][10] or the 2013 Federal Register determination [18] — the same numeric anchor is used throughout. External links open to PubMed, PubMed Central, the publishing journal, or the FDA / Federal Register source repository. ## Pediatric efficacy **[1]** Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S; International Multicenter GHRH Study Group. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. *Journal of Clinical Endocrinology & Metabolism*. 1996;81(3):1189-1196. DOI: 10.1210/jcem.81.3.8772599. PMID: 8772599. https://pubmed.ncbi.nlm.nih.gov/8772599/ **[2]** Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. *BioDrugs*. 1999;12(2):139-157. DOI: 10.2165/00063030-199912020-00007. PMID: 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/ **[5]** Wit JM, Kamp GA, Rikken B. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. *Journal of Clinical Endocrinology & Metabolism*. 1994;79(5):1349-1356. DOI: 10.1210/jcem.79.5.7962328. PMID: 7955460. https://pubmed.ncbi.nlm.nih.gov/7955460/ ## Adult aging-axis and somatopause **[3]** Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. *Journal of Clinical Endocrinology & Metabolism*. 1992;75(2):530-535. DOI: 10.1210/jcem.75.2.1379256. PMID: 1379256. https://pubmed.ncbi.nlm.nih.gov/1379256/ **[4]** Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. *Journal of Clinical Endocrinology & Metabolism*. 1997;82(5):1472-1479. DOI: 10.1210/jcem.82.5.3943. PMID: 9141537. https://academic.oup.com/jcem/article-abstract/82/5/1472/2823341 **[11]** Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? *Clinical Interventions in Aging*. 2006;1(4):307-308. DOI: 10.2147/ciia.2006.1.4.307. PMID: 18046908. https://pubmed.ncbi.nlm.nih.gov/18046908/ **[15]** Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, Domínguez-Mendoza AE, Barrera-Barrera SA, Barrera-Saldaña HA. Growth hormone and aging: a clinical review. *Frontiers in Aging*. 2025;6:1549453. DOI: 10.3389/fragi.2025.1549453. PMID: 40260058. https://pmc.ncbi.nlm.nih.gov/articles/PMC12009952/ ## Cognitive trials **[7]** Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. *Archives of Neurology*. 2012;69(11):1420-1429. DOI: 10.1001/archneurol.2012.1970. PMID: 22869065. https://pmc.ncbi.nlm.nih.gov/articles/PMC3764914/ **[8]** Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. *JAMA Neurology*. 2013;70(7):883-890. DOI: 10.1001/jamaneurol.2013.1425. PMID: 23689947. https://jamanetwork.com/journals/jamaneurology/fullarticle/1696089 **[9]** Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone-releasing hormone improves the cognition of healthy older adults. *Neurobiology of Aging*. 2006;27(2):318-323. DOI: 10.1016/j.neurobiolaging.2005.01.010. PMID: 16399218. https://www.sciencedirect.com/science/article/abs/pii/S0197458005000631 **[17]** Winston CN, Goetzl EJ, Baker LD, Vitiello MV, Rissman RA. Growth hormone-releasing hormone modulation of neuronal exosome biomarkers in mild cognitive impairment. *Journal of Alzheimer's Disease*. 2018;66(3):971-981. DOI: 10.3233/JAD-180302. PMID: 30372680. https://journals.sagepub.com/doi/10.3233/JAD-180302 ## Mechanism and receptor signaling **[12]** Cui T, Jimenez JJ, Block NL, Badiavas EV, Rodriguez-Menocal L, Vila Granda A, Cai R, Sha W, Zarandi M, Perez R, Schally AV. Agonistic analogs of growth hormone-releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways. *Oncotarget*. 2016;7(33):52661-52672. DOI: 10.18632/oncotarget.11024. PMID: 27623072. https://pmc.ncbi.nlm.nih.gov/articles/PMC5288139/ **[13]** Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. *Reviews in Endocrine and Metabolic Disorders*. 2025;26(3):343-352. DOI: 10.1007/s11154-025-09952-x. PMID: 39934495. https://pmc.ncbi.nlm.nih.gov/articles/PMC12137518/ **[16]** Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. *JCSM Rapid Communications*. 2020;3(1):25-37. DOI: 10.1002/rco2.9. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 ## Pharmacokinetics, safety, and historic labeling **[6]** Sermorelin acetate injection — historic FDA-approved prescribing information (NDA 020443). Pharmacokinetics, indications, and dosing labeling. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443 **[10]** Sermorelin acetate injection — historic FDA-approved prescribing information (NDA 020443). Adverse-event summary and safety record from the pediatric registration trial dataset. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443 ## Regulatory and clinical practice context **[14]** Caputo M, Mele C, Ferrero A, Leone I, Daffara T, Marzullo P, Prodam F, Aimaretti G. A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to real life. *Journal of Clinical Medicine*. 2024;13(20):6079. DOI: 10.3390/jcm13206079. PMID: 39458029. https://www.mdpi.com/2077-0383/13/20/6079 **[18]** U.S. Food and Drug Administration. Determination That Sermorelin Acetate Injection (the formerly approved finished product), 0.5 mg/vial, 1.0 mg/vial, and 0.05 mg/amp, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. *Federal Register*. 2013;78 FR 14114. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams ## References [1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S; International Multicenter GHRH Study Group. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology & Metabolism. 1996;81(3):1189-1196. https://pubmed.ncbi.nlm.nih.gov/8772599/ [2] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/ [3] Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/ [4] Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. https://academic.oup.com/jcem/article-abstract/82/5/1472/2823341 [5] Wit JM, Kamp GA, Rikken B. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Journal of Clinical Endocrinology & Metabolism. 1994;79(5):1349-1356. https://pubmed.ncbi.nlm.nih.gov/7955460/ [6] Sermorelin acetate injection — historic FDA-approved prescribing information (NDA 020443). Pharmacokinetics, indications, and dosing labeling. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443 [7] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. https://pmc.ncbi.nlm.nih.gov/articles/PMC3764914/ [8] Friedman SD, Baker LD, Borson S, Jensen JE, Barsness SM, Craft S, Merriam GR, Otto RK, Novotny EJ, Vitiello MV. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology. 2013;70(7):883-890. https://jamanetwork.com/journals/jamaneurology/fullarticle/1696089 [9] Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone-releasing hormone improves the cognition of healthy older adults. Neurobiology of Aging. 2006;27(2):318-323. https://www.sciencedirect.com/science/article/abs/pii/S0197458005000631 [10] Sermorelin acetate injection — historic FDA-approved prescribing information (NDA 020443). Adverse-event summary and safety record from the pediatric registration trial dataset. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443 [11] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/ [12] Cui T, Jimenez JJ, Block NL, Badiavas EV, Rodriguez-Menocal L, Vila Granda A, Cai R, Sha W, Zarandi M, Perez R, Schally AV. Agonistic analogs of growth hormone-releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways. Oncotarget. 2016;7(33):52661-52672. https://pmc.ncbi.nlm.nih.gov/articles/PMC5288139/ [13] Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Reviews in Endocrine and Metabolic Disorders. 2025;26(3):343-352. https://pmc.ncbi.nlm.nih.gov/articles/PMC12137518/ [14] Caputo M, Mele C, Ferrero A, Leone I, Daffara T, Marzullo P, Prodam F, Aimaretti G. A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to real life. Journal of Clinical Medicine. 2024;13(20):6079. https://www.mdpi.com/2077-0383/13/20/6079 [15] Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, Domínguez-Mendoza AE, Barrera-Barrera SA, Barrera-Saldaña HA. Growth hormone and aging: a clinical review. Frontiers in Aging. 2025;6:1549453. https://pmc.ncbi.nlm.nih.gov/articles/PMC12009952/ [16] Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 [17] Winston CN, Goetzl EJ, Baker LD, Vitiello MV, Rissman RA. Growth hormone-releasing hormone modulation of neuronal exosome biomarkers in mild cognitive impairment. Journal of Alzheimer's Disease. 2018;66(3):971-981. https://journals.sagepub.com/doi/10.3233/JAD-180302 [18] U.S. Food and Drug Administration. Determination That Sermorelin Acetate Injection (the formerly approved finished product), 0.5 mg/vial, 1.0 mg/vial, and 0.05 mg/amp, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78 FR 14114. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams [19] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Annals of Internal Medicine. 2008;149(9):677-679. https://pubmed.ncbi.nlm.nih.gov/18981489/ [20] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nature Reviews Endocrinology. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/ [21] Munafo A, Nguyen TX, Papasouliotis O, et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH release in elderly subjects. European Journal of Endocrinology. 2005;153(3):353-361. https://pubmed.ncbi.nlm.nih.gov/16061831/ [22] Esposito S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021;14(3):448-460. https://pubmed.ncbi.nlm.nih.gov/34665524/ --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription. --- # About Sermorelin Meds — editorial reading room for the GHRH(1-29) literature > Sermorelin Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin acetate. We are not a clinic. We do not sell anything. Editorial standards, sourcing methodology, and the modifier in the domain name explained. What this site is, what it is not, and how the 'meds' modifier in the domain name should be read. ## What this site is Sermorelin Meds is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin acetate — the 29-amino-acid GHRH(1-29) peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The research summaries on this site are organized around a small, deliberately constrained set of primary sources: the original pediatric and adult GHRH(1-29) controlled trials, the historic FDA-approved prescribing information, the 2013 Federal Register determination governing post-discontinuation compounding, and recent peer-reviewed reviews of the GHRH-R receptor and the somatopause clinical landscape. Every quantitative claim on the site cites one of those sources. Where a finding is qualitative or contested, the text says so. ## How to read the modifier in the domain name The 'meds' in the domain is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services. We are not a pharmacy. We do not dispense medication. We do not write prescriptions. The framing simply names the editorial lane: this is the place to read about sermorelin **as a medication** — its FDA-approval history under NDA 020443, its 2008 commercial discontinuation, its current 503A compounding status, and what the controlled trials in pediatric GHD and adult somatopause have shown. The distinction matters because sermorelin's regulatory history is unusual. It is one of very few research peptides with a documented FDA approval, a documented withdrawal, and a documented Federal Register finding (78 FR 14114) that the withdrawal was not for safety or efficacy reasons. The medication-history lens is the right one for reading that record — but a medication-history reading room is not a pharmacy, and we want that distinction clear. ## Editorial standards Sources are restricted to peer-reviewed primary literature, peer-reviewed reviews, FDA documents, and Federal Register notices. We cite PubMed, PubMed Central, the publishing journal, the FDA, and the Federal Register directly — never aggregators, never vendor product pages, never marketing materials. We do not recommend doses. We document the doses that appear in the historic FDA-approved label and in published research trials, and we identify each as such. We do not interpret findings beyond what the source authors themselves report. Where the literature is sparse — for example, on sublingual sermorelin bioavailability — we say so plainly rather than fill the gap with speculation. We use generic compound names throughout (sermorelin, GHRH(1-29), tesamorelin, ipamorelin, CJC-1295) and avoid registered drug brand names. We do not link to other portfolio sites and we do not link out to vendors, pharmacies, or marketing pages of any kind. ## What this site does not do We do not sell sermorelin or any other product. We do not prescribe. We do not dispense. We do not offer telehealth, consultations, or treatment plans. We do not refer to specific compounding pharmacies, specific clinicians, or specific patient services. We do not maintain a patient roster or a customer database. The site exists to make the published research on a specific compound easier to read — for human readers and for machine readers. The editorial standards are simple: every quantitative claim cites the primary source it comes from; where the literature is sparse or contested, the text says so plainly. --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription. --- # Contact Sermorelin Meds — editorial corrections and reading-room inquiries > Contact the editorial team behind Sermorelin Meds for corrections, citation requests, or reading-room inquiries. Not a clinical service, not a pharmacy, and not for medical advice. For corrections, missing citations, or methodology questions. Not for medical advice — please see your clinician. ## When to write Please reach out if you have spotted a factual error, an out-of-date citation, a broken link to a primary source, or a peer-reviewed reference we should consider adding. Methodology and editorial-process questions are also welcome — we can describe how a particular claim on the site was sourced and which paragraph of which paper supports it. Please do **not** write for medical advice. We are not clinicians; we cannot tell you whether sermorelin is appropriate for any individual circumstance; and we have no information about specific compounding pharmacies, specific clinicians, or specific dosing protocols beyond what is published in the peer-reviewed literature and on this site. For medical questions about your own situation, please consult a licensed healthcare provider in your jurisdiction. ## Contact form Use the form below to send a message to the editorial team. Fields marked with an asterisk are required. Messages are reviewed in batches; please allow several business days for a reply, and longer for citation requests that require us to track down a specific source. - **Name** * - **Email** * - **Topic** (correction, citation request, methodology question, other) * - **Message** * No attachments, no protected health information, and please no individual patient details — this is an editorial inbox, not a clinical one. ## What we cannot help with We cannot recommend a compounding pharmacy. We cannot recommend a clinician. We cannot review your laboratory values, suggest a dose, comment on whether sermorelin is appropriate for your situation, or facilitate any kind of product purchase. We do not sell sermorelin and we are not affiliated with any vendor or compounding pharmacy. This site is an editorial reading room for the published research literature on the GHRH(1-29) peptide. The contact channel exists to keep that reading room accurate and well-cited. Everything else is outside our scope. --- An independent literature digest of peer-reviewed research on the GHRH(1-29) circuit — not a clinic, not a pharmacy, not a prescription.